Please login to the form below

Not currently logged in

Symkevi approval in Europe helps Vertex expand CF treatment

The new combination has shown greater efficacy than Orkambi and with fewer side effects


Vertex has announced the European Union approval of its new two-drug combination Symkevi (tezacaftor/ivacaftor), which helps expand treatment to a far larger number of cystic fibrosis (CF) patients.

The company has pioneered treatment of CF with Kalydeco (ivacaftor) and combination Orkambi (lumacaftor/ivacaftor), but the latter can only be used in the 45% of patients who have two copies of the F508del mutation.

The new combination has been shown to be effective in a far larger group of patients, and the company now says that the vast majority of the world’s CF patients will be eligible for treatment with one or more of their drugs.

Symkevi combines ivacaftor with a new agent texacaftor and is licensed to treat people with cystic fibrosis aged 12 and older who either have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, or one copy of the F508del mutation and a copy of one of 14 mutations in which the CFTR protein shows residual activity.

“Today marks an important milestone for many CF patients in Europe, including those who so far have had no available option to treat the CFTR protein defect responsible for their disease,” said Reshma Kewalramani, MD, executive vice president, Global Medicines Development and Medical Affairs and chief medical officer at Vertex. “With today’s Marketing Authorisation, we are rapidly moving towards treating 90% of CF patients.”

The new combination was approved by the FDA and is known as Symdeko in the US and Canada. Its approval on both sides of the Atlantic will now boost Vertex’s sales forecasts considerably, with analysts predicting the firm’s revenues will jump to $3.75bn next year, up from a forecast $2.17bn this year.

The new combination has shown greater efficacy than Orkambi and with fewer side effects, something which should help it become a commercial success in key markets.

Gaining market access in Europe is far from straightforward however, especially in England, home to one of the highest numbers of CF patients anywhere in the world.

Vertex has been in an ugly standoff with budget holder NHS England over pricing and reimbursement of Orkambi, with a stalemate meaning most patients in the country still can’t access the drug.

The imminent arrival of Symkevi had been factored into the pricing negotiations, but Vertex has rejected an NHS England offer that “provides the potential” for Vertex to secure revenues of £1bn over the next 10 years from Orkambi, Kalydeco and Symkevi without having to gain NICE approval.

The last offer from NHS England for an average of all of Vertex’s CF medicines is a nearly 90% discount on what Germany pays for one of Vertex’s medicines.

Article by
Andrew McConaghie

2nd November 2018

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...